These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

616 related items for PubMed ID: 22337241

  • 21. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
    Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y.
    Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and safety of infliximab in the treatment of Kawasaki disease: A systematic review and meta-analysis.
    Wang L, He M, Wang W, Li S, Zhao G.
    Eur J Pediatr; 2024 Apr; 183(4):1765-1776. PubMed ID: 38240765
    [Abstract] [Full Text] [Related]

  • 23. [Plasma exchange therapy for Kawasaki disease refractory to intravenous immunoglobulin].
    Mori M.
    Nihon Rinsho; 2008 Feb; 66(2):349-54. PubMed ID: 18260334
    [Abstract] [Full Text] [Related]

  • 24. The effect of TNFalpha blockade in complicated, refractory Kawasaki disease.
    Stenbøg EV, Windelborg B, Hørlyck A, Herlin T.
    Scand J Rheumatol; 2006 Feb; 35(4):318-21. PubMed ID: 16882598
    [Abstract] [Full Text] [Related]

  • 25. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
    Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glodé MP, Dominguez SR.
    Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447
    [Abstract] [Full Text] [Related]

  • 26. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].
    Qin LJ, Wang HW, Hu XF, Liu QJ, Shi H, Wei YX, Chen QJ, Cheng PX.
    Zhonghua Er Ke Za Zhi; 2006 Dec; 44(12):891-5. PubMed ID: 17254453
    [Abstract] [Full Text] [Related]

  • 27. Kawasaki disease: a comprehensive review of treatment options.
    Patel RM, Shulman ST.
    J Clin Pharm Ther; 2015 Dec; 40(6):620-5. PubMed ID: 26547265
    [Abstract] [Full Text] [Related]

  • 28. Intravenous immunoglobulin preparation type: association with outcomes for patients with acute Kawasaki disease.
    Manlhiot C, Yeung RS, Chahal N, McCrindle BW.
    Pediatr Allergy Immunol; 2010 May; 21(3):515-21. PubMed ID: 20546528
    [Abstract] [Full Text] [Related]

  • 29. [Clinical features and course of Kawasaki disease in central Tunisia: a study about 14 cases collected over a period of three years (2000-2002)].
    Chemli J, Kchaou H, Amri F, Belkadhi A, Essoussi AS, Gueddiche N, Harbi A.
    Tunis Med; 2005 Aug; 83(8):477-83. PubMed ID: 16238276
    [Abstract] [Full Text] [Related]

  • 30. Clinical responses of patients with Kawasaki disease to different brands of intravenous immunoglobulin.
    Tsai MH, Huang YC, Yen MH, Li CC, Chiu CH, Lin PY, Lin TY, Chang LY.
    J Pediatr; 2006 Jan; 148(1):38-43. PubMed ID: 16423595
    [Abstract] [Full Text] [Related]

  • 31. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease.
    Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S.
    J Pediatr; 2000 Aug; 137(2):177-80. PubMed ID: 10931408
    [Abstract] [Full Text] [Related]

  • 32. Infliximab plus plasma exchange rescue therapy in Kawasaki disease.
    Sonoda K, Mori M, Hokosaki T, Yokota S.
    J Pediatr; 2014 May; 164(5):1128-1132.e1. PubMed ID: 24560183
    [Abstract] [Full Text] [Related]

  • 33. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.
    Roberts SC, Jain S, Tremoulet AH, Kim KK, Burns JC, KIDCARE Multicenter Study Group, Anand V, Anderson M, Ang J, Ansusinha E, Arditi M, Ashouri N, Bartlett A, Chatterjee A, DeBiasi R, Dekker C, DeZure C, Didion L, Dominguez S, El Feghaly R, Erdem G, Halasa N, Harahsheh A, Jackson MA, Jaggi P, Jain S, Jone PN, Kaushik N, Kurio G, Lillian A, Lloyd D, Manaloor J, McNelis A, Michalik DE, Newburger J, Newcomer C, Perkins T, Portman M, Romero J, Ronis T, Rowley A, Schneider K, Schuster J, Tejtel SKS, Sharma K, Simonsen K, Szmuszkovicz J, Truong D, Wood J, Yeh S.
    Contemp Clin Trials; 2019 Apr; 79():98-103. PubMed ID: 30840903
    [Abstract] [Full Text] [Related]

  • 34. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
    Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, Oki I, Ogino H, Schonberger LB, Yanagawa H.
    Pediatr Infect Dis J; 2008 Feb; 27(2):155-60. PubMed ID: 18174868
    [Abstract] [Full Text] [Related]

  • 35. Kawasaki disease: part II. Complications and treatment.
    Bayers S, Shulman ST, Paller AS.
    J Am Acad Dermatol; 2013 Oct; 69(4):513.e1-8; quiz 521-2. PubMed ID: 24034380
    [Abstract] [Full Text] [Related]

  • 36. Altered immunoglobulin A and M levels associated with changes in BAFF and APRIL after administration of intravenous immunoglobulin to treat Kawasaki disease.
    Doi M, Takeda T, Sakurai Y, Kato J, Hayashi T, Fukuda K, Takase T, Shima M.
    J Investig Allergol Clin Immunol; 2010 Oct; 20(5):413-8. PubMed ID: 20945608
    [Abstract] [Full Text] [Related]

  • 37. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children.
    Wooditch AC, Aronoff SC.
    Pediatrics; 2005 Oct; 116(4):989-95. PubMed ID: 16199713
    [Abstract] [Full Text] [Related]

  • 38. Elevated D-dimer level is a risk factor for coronary artery lesions accompanying intravenous immunoglobulin-unresponsive Kawasaki disease.
    Masuzawa Y, Mori M, Hara T, Inaba A, Oba MS, Yokota S.
    Ther Apher Dial; 2015 Apr; 19(2):171-7. PubMed ID: 25257673
    [Abstract] [Full Text] [Related]

  • 39. A report of two cases of Kawasaki disease treated with plasma exchange.
    Harada T, Ito S, Shiga K, Inaba A, Machida H, Aihara Y, Yokota S.
    Ther Apher Dial; 2008 Apr; 12(2):176-9. PubMed ID: 18387169
    [Abstract] [Full Text] [Related]

  • 40. [Risk factors for coronary artery lesions in children with Kawasaki disease].
    Li Y, Wang XM, Liu YL, Shi K, Yang YF, Guo YH.
    Zhongguo Dang Dai Er Ke Za Zhi; 2012 Dec; 14(12):938-41. PubMed ID: 23234782
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.